Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 14
2004 13
2005 13
2006 10
2007 8
2008 9
2009 9
2010 9
2011 10
2012 8
2013 22
2014 18
2015 29
2016 19
2017 26
2018 30
2019 31
2020 45
2021 43
2022 52
2023 39
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban, Rivaroxaban or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2.
Sueta D, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Kaneda K, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takeda T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Shioyama W, Dohke T, Nishikawa R, Kimura T, Tsujita K. Sueta D, et al. Among authors: ikeda s. Thromb Haemost. 2024 Apr 29. doi: 10.1055/a-2316-5269. Online ahead of print. Thromb Haemost. 2024. PMID: 38684190 Clinical Trial.
Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism.
Nishimoto Y, Yamashita Y, Morimoto T, Chatani R, Kaneda K, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Sato Y, Watanabe T, Yamada T, Fukunami M, Kimura T; COMMAND VTE Registry-2 Investigators. Nishimoto Y, et al. Among authors: ikeda s. Eur J Intern Med. 2024 Apr 24:S0953-6205(24)00171-7. doi: 10.1016/j.ejim.2024.04.012. Online ahead of print. Eur J Intern Med. 2024. PMID: 38664165
Subclass phenotypes in patients with unprovoked venous thromboembolisms using a latent class analysis.
Ikeda S, Yamashita Y, Morimoto T, Chatani R, Kaneda K, Nishimoto Y, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Sueta D, Shioyama W, Dohke T, Nishikawa R, Ono K, Kimura T. Ikeda S, et al. Thromb Res. 2024 Apr 19;238:27-36. doi: 10.1016/j.thromres.2024.04.017. Online ahead of print. Thromb Res. 2024. PMID: 38653180
Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study.
Chatani R, Yamashita Y, Morimoto T, Muraoka N, Umetsu M, Nishimoto Y, Takada T, Ogihara Y, Nishikawa T, Ikeda N, Otsui K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mushiake K, Kadota K, Ono K, Kimura T. Chatani R, et al. Among authors: ikeda s. Eur Heart J Cardiovasc Pharmacother. 2024 Apr 22:pvae028. doi: 10.1093/ehjcvp/pvae028. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38650055
Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study.
Yamashita Y, Yachi S, Takeyama M, Nishimoto Y, Tsujino I, Nakamura J, Yamamoto N, Nakata H, Ikeda S, Umetsu M, Aikawa S, Hayashi H, Satokawa H, Okuno Y, Iwata E, Ogihara Y, Ikeda N, Kondo A, Iwai T, Yamada N, Ogawa T, Kobayashi T, Mo M; Clot-COVID Study Investigators. Yamashita Y, et al. Among authors: ikeda s. Ann Vasc Dis. 2024 Mar 25;17(1):1-8. doi: 10.3400/avd.oa.23-00031. Epub 2023 Nov 28. Ann Vasc Dis. 2024. PMID: 38628927 Free PMC article.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: ikeda s. Target Oncol. 2024 Apr 13. doi: 10.1007/s11523-024-01048-x. Online ahead of print. Target Oncol. 2024. PMID: 38613731
436 results